论文部分内容阅读
目的探讨联合使用P504s、P63、34βE12双染标记前列腺组织标本早期诊断及鉴别诊断前列腺癌的可行性、特异性、敏感性以及临床应用价值。方法使用P504s单抗、P63单抗、34βE12单抗先后在同一前列腺穿刺活检组织标本上行前列腺腺泡细胞和基底细胞免疫组化双重标记染色。P504s表达于癌变的前列腺细胞浆;P63表达于前列腺基底细胞核,34βE12表达于前列腺基底细胞浆。结果 P504s表达阳性而34βE12和P63表达阴性或不连续表达提示为前列腺癌,并可行Gleason评分;P504s表达阳性、34βE12和P63完整阳性表达提示前列腺上皮内瘤;504s表达阴性、34βE12和P63连续阳性表达提示良性前列腺病变。结论通过联合使用P504s、P63和34βE12在同一前列腺标本上进行双重染色标记前列腺癌变细胞、前列腺基底细胞,通过观察前列腺基底细胞的完整性、前列腺癌细胞的形态学表现等可以有效诊断和鉴别前列腺癌、前列腺上皮内肿瘤(PIN)、良性前列腺增生等,增加对前列腺癌的早期诊断率和诊断的准确性,促进临床前列腺癌的早期治疗。
Objective To investigate the feasibility, specificity, sensitivity and clinical value of early diagnosis and differential diagnosis of prostate cancer by using P504s, P63,34βE12 double staining prostatic tissue specimens. Methods P504s monoclonal antibody, P63 monoclonal antibody and 34βE12 monoclonal antibody were stained with double-labeled immunohistochemical double staining of prostatic acinar cells and basal cells in the same prostate biopsy tissue. P504s is expressed in cancerous prostate cytoplasm; P63 is expressed in prostatic basal cell nucleus and 34βE12 is expressed in prostatic basal cell cytoplasm. Results The expression of P504s was positive and the expression of 34βE12 and P63 was negative or discontinuous, which suggested that it was prostate cancer. The Gleason score was also available. The positive expression of P504s and the positive expression of 34βE12 and P63 were positive for prostate cancer. The expression of 504s was negative and the expression of 34βE12 and P63 were positive Prompted benign prostatic lesions. Conclusions P504s, P63 and 34βE12 can be used to label prostate cancer cells and prostatic basal cells by double staining on the same prostatic specimens. Prostate cancer can be effectively diagnosed and differentiated by observing the integrity of prostatic basal cells and the morphological features of prostate cancer cells. , Prostatic intraepithelial neoplasia (PIN), benign prostatic hyperplasia, etc., to increase the early diagnosis of prostate cancer and diagnostic accuracy, and promote the early treatment of clinical prostate cancer.